We have reviewed our interactions between the HDV drug bulevirtide and CYP3A4, OATP1B1/3, and NTCP substrates. Ninty interactions have been revised, with non-narrow therapeutic index drugs downgraded to a non-clinically significant drug interaction. These changes reflect the difference between the recommended dose of bulevirtide (2 mg) vs the studied dose (10 mg).
The interactions between bulevirtide and the following comedications have changed from AMBER to YELLOW.
- Ambrisentan (Hypertension/Heart Failure Agents)
- Apixaban (Anticoagulant, Anti-platelet and Fibrinolytic)
- Atorvastatin (Lipid Lowering Agents)
- Bosentan (Hypertension/Heart Failure Agents)
- Brincidofovir (Antivirals)
- Elbasvir/grazoprevir (Hepatitis C Directly Acting Antivirals, DAAs)
- Fentanyl (recreational) (Illicit/Recreational)
- Fexofenadine (Antihistamines)
- Fluvastatin (Lipid Lowering Agents)
- Glecaprevir/pibrentsavir (Hepatitis C Directly Acting Antivirals, DAAs)
- Glibenclamide (Antidiabetics)
- Hydrocodone (Analgesics)
- Lovastatin (Lipid Lowering Agents)
- Nateglinide (Antidiabetics)
- Olmesartan (Hypertension/Heart Failure Agents)
- Oxycodone (Analgesics)
- Paclitaxel (Cancer Therapies)
- Panobinostat (Cancer Therapies)
- Pitavastatin (Lipid Lowering Agents)
- Ponatinib (Cancer Therapies)
- Pravastatin (Lipid Lowering Agents)
- Repaglinide (Antidiabetics)
- Rivaroxaban (Anticoagulant, Anti-platelet and Fibrinolytic)
- Rosuvastatin (Lipid Lowering Agents)
- Sacubritil/valsartan (Hypertension/Heart Failure Agents)
- Sofosbuvir/velpatasvir/voxilaprevir (Hepatitis C Directly Acting Antivirals, DAAs)
- Telmisartan (Hypertension/Heart Failure Agents)
- Valsartan (Hypertension/Heart Failure Agents)
